Ruxolitinib not checked
Novartis · INCB018424 cream · INCB018424 phosphate cream
FollowEvery change as it happens, and a Monday email
Trials
30 active
84 in total · 30 in the EU
What this is
- How it works
- Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.Kinase Inhibitor; Janus Kinase Inhibitor FDA class
- How it’s given
- “Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.”In the company’s words, NCT06462469 on ClinicalTrials.gov
- Tested for
- Hidradenitis Suppurativa (3 trials), Primary Myelofibrosis (2 trials), Myelofibrosis (2 trials), NonSegmental Vitiligo (2 trials), Primary Myelofibrosis (PMF) (2 trials), Myeloproliferative Neoplasms (2 trials), Steroid-refractory Acute Graft Versus Host Disease, Graft vs. Host Disease and 29 more
- Main trialPhase 4
- “The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).”In the company’s words, NCT06462469 on ClinicalTrials.gov
- Other names
- INCB018424 cream · INCB018424 phosphate cream · Opzelura · INCB18424 cream · INCB018424 · Oral Jak Inhibitor · Jakafi · Jakavi · INC424 · Jakavi/Jakafi
- Given with
- Diprolene (Organon), Dovonex (LEO Pharm)Other companies’ drugs in its trials
Other drugs for Hidradenitis Suppurativa
- BimekizumabUCB Biopharma SRL · Phase 3
- PovorcitinibIncyte Corporation · Phase 3
- LutikizumabAbbVie · Phase 3
- RemibrutinibNovartis · Phase 3
- BFB759Bluefin Biomedicine, Inc. · Phase 2/3
- SonelokimabMoonLake Immunotherapeutics AG · Phase 3
Copies tested against it1
Other companies’ versions, mostly cheaper copies for when the patent ends
- Ruxolitinib Topical Cream 1.5%Sun Pharmaceutical Industries, Inc. · NCT06673654 · finished
Coming up12
- 9 DecPhase 1 trial completes · ClinicalTrials.gov
- 30 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- 29 Feb 2028Phase 1 trial completes · ClinicalTrials.gov
- 17 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 5 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 29 Oct 2028Phase 1 trial completes · ClinicalTrials.gov
- 10 May 2029Phase 4 trial completes · ClinicalTrials.gov
- 31 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
- 17 Jan 2031Phase 3 trial completes · ClinicalTrials.gov
- 5 Apr 2032Phase 4 trial completes · ClinicalTrials.gov
Changes3
Last 90 days- 12 NovCompletion date moved: 2027-06-02 to 2029-12-31 · ClinicalTrials.gov NCT06401356
- 12 NovCompletion date moved: 2026-10-09 to 2026-10-29 · ClinicalTrials.gov NCT06959225
- 9 NovCompletion date moved: 2026-10-09 to 2026-10-01 · ClinicalTrials.gov NCT06958211
Trials84
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 3 Sep 2026 | Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease | |
| Phase 4Recruiting | 10 May 2029 | Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease | |
| Phase 4Active, not recruiting | 5 Apr 2032 | CINC424A2X01B Rollover Protocol | |
| Phase 3Active, not recruiting | 23 Aug 2023 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | |
| Phase 3Active, not recruiting | 7 Aug 2026 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis | |
| Phase 3Active, not recruiting | 1 Oct 2026 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | |
| Phase 3Active, not recruiting | 29 Oct 2026 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | |
| Phase 3Recruiting | 30 Apr 2027 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | |
| Phase 3Recruiting | 17 May 2028 | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | |
| Phase 3Recruiting | 5 Jun 2028 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | |
| Phase 3Recruiting | 31 Dec 2029 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | |
| Phase 3Recruiting | 17 Jan 2031 | A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) | |
| Phase 2Active, not recruiting | 1 Oct 2026 | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | |
| Phase 2Active, not recruiting | 5 Nov 2026 | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | |
| Phase 2Active, not recruiting | 30 Sep 2027 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | |
| Phase 1Active, not recruiting | 23 Jul 2026 | Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis | |
| Phase 1Recruiting | 9 Dec 2026 | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | |
| Phase 1Active, not recruiting | 30 Apr 2027 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | |
| Phase 1Active, not recruiting | 29 Feb 2028 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | |
| Phase 1Recruiting | 29 Oct 2028 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | |
| Phase 4Terminated | 22 Jan 2025 | The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. | |
| Phase 3Completed | 29 Sep 2015 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | |
| Phase 3Completed | 24 Jun 2019 | Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation | |
| Phase 3Completed | 18 Nov 2019 | TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | |
| Phase 3Completed | 23 Dec 2019 | Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | |
| Phase 3Completed | 8 May 2020 | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) | |
| Phase 3Completed | 17 Oct 2020 | Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm | |
| Phase 3Terminated | 26 Feb 2021 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | |
| Phase 3Completed | 15 Mar 2021 | Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) | |
| Phase 3Completed | 18 Mar 2021 | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) | |
| Phase 3Completed | 14 Nov 2022 | Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | |
| Phase 3Completed | 10 May 2023 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) | |
| Phase 3Terminated | 3 Aug 2023 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | |
| Phase 3Terminated | 16 Aug 2023 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | |
| Phase 3Withdrawn | 25 Apr 2024 | Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 | |
| Phase 3Withdrawn | 25 Apr 2024 | Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 | |
| Phase 3Completed | 17 May 2024 | Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis | |
| Phase 3Completed | 7 Oct 2024 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | |
| Phase 3Completed | 30 Dec 2024 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | |
| Phase 3Completed | 21 May 2025 | A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | |
| Phase 2Completed | 31 Jan 2009 | A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis | |
| Phase 2Completed | 30 Apr 2009 | Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis | |
| Phase 2Completed | 26 Jun 2009 | A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis | |
| Phase 2Terminated | 20 Jun 2010 | Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia | |
| Phase 2Completed | 10 Jan 2018 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis | |
| Phase 2Completed | 31 Jan 2018 | A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) | |
| Phase 2Completed | 12 Sep 2018 | A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | |
| Phase 2Completed | 14 Mar 2020 | A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis | |
| Phase 2Terminated | 3 Aug 2020 | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | |
| Phase 2Terminated | 28 Jan 2021 | A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | |
| Phase 2Completed | 25 Feb 2022 | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant | |
| Phase 2Completed | 17 Nov 2022 | A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) | |
| Phase 2Completed | 18 Nov 2022 | The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis | |
| Phase 2Completed | 3 Aug 2023 | Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement | |
| Phase 2Completed | 1 Sep 2023 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus | |
| Phase 2Completed | 2 Oct 2023 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus | |
| Phase 2Completed | 19 Oct 2023 | Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa | |
| Phase 2Completed | 15 Jul 2024 | Topical Ruxolitinib Evaluation in Chronic Hand Eczema | |
| Phase 2Completed | 6 Mar 2025 | A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo | |
| Phase 2Completed | 3 Mar 2026 | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | |
| Phase 1/2Terminated | 13 Feb 2019 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | |
| Phase 1/2Terminated | 11 Aug 2020 | Study of INCB053914 in Subjects With Advanced Malignancies | |
| Phase 1/2Completed | 11 Mar 2021 | Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease | |
| Phase 1/2Terminated | 3 May 2023 | Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients | |
| Phase 1/2Completed | 1 Apr 2025 | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders | |
| Phase 1Completed | 31 Dec 2019 | Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) | |
| Phase 1Completed | 22 Jun 2020 | Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis | |
| Phase 1Completed | 9 Nov 2020 | Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis | |
| Phase 1Completed | 7 Aug 2023 | Study of Ruxolitinib Cream in Children With Atopic Dermatitis | |
| Phase 1Completed | 16 Apr 2024 | A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants. | |
| Phase 1Completed | 25 Oct 2024 | A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants | |
| Phase 1Completed | 8 Sep 2026 | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants | |
| Phase 1/2Authorised | not given | International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol C | |
| Phase 2Ended | not given | JAKAHDI - JAK inhibitors in acquired hemophagocytic syndrome in the ICU | |
| Phase 2Authorised | not given | BIGTIM: Blocking Interferon-γ by ruxolitinib for Treating Inclusion body Myositis: a phase IIb trial. | |
| Phase 2Authorised | not given | Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP | |
| Phase 1Ended | not given | Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Treatment, Two-Sequence, Two-Period Crossover Study in Healthy Participants Under Fasting Conditions. | |
| Phase 2Authorised | not given | Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEAT Trial | |
| Phase 2Authorised | not given | R-HLH - Efficacy of Ruxolitinib as first line treatment in primary haemophagocytic lymphohistiocytosis (HLH) in children: a Phase 2, multicentre, non-comparative study | |
| Phase 3Authorised | not given | MITHRIDATE: A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high risk polycythemia vera | |
| Phase 2Authorised | not given | Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study. | |
| Phase 2/3Authorised | not given | Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. | |
| Phase 2Authorised | not given | A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL) | |
| Phase 2/3Authorised | not given | Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026